68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients

Stefan A. Koerber, Leon Will, Clemens Kratochwil, Matthias F. Haefner, Hendrik Rathke, Christophe Kremer, Jonas Merkle, Klaus Herfarth, Klaus Kopka, Peter L. Choyke, Tim Holland-Letz, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The present study analyzed the impact of 68 Ga-labeled prostate-specific membrane antigen-HBED-CC ( 68 Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68 Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0% and 44.0% of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3%, respectively. Conclusion: 68 Ga-PSMA-11 PET/ CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.

Original languageEnglish (US)
Pages (from-to)234-240
Number of pages7
JournalJournal of Nuclear Medicine
Volume60
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Prostate
Carcinoma
Prostate-Specific Antigen
Prostatic Neoplasms
Neoplasm Staging
Therapeutics
Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
Recurrence
Neoplasms

Keywords

  • PET/CT
  • PSMA
  • Prostate cancer
  • Radiotherapy
  • Staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma : Implications for radiotherapeutic management in 121 patients. / Koerber, Stefan A.; Will, Leon; Kratochwil, Clemens; Haefner, Matthias F.; Rathke, Hendrik; Kremer, Christophe; Merkle, Jonas; Herfarth, Klaus; Kopka, Klaus; Choyke, Peter L.; Holland-Letz, Tim; Haberkorn, Uwe; Debus, Juergen; Giesel, Frederik L.

In: Journal of Nuclear Medicine, Vol. 60, No. 2, 01.02.2019, p. 234-240.

Research output: Contribution to journalArticle

Koerber, SA, Will, L, Kratochwil, C, Haefner, MF, Rathke, H, Kremer, C, Merkle, J, Herfarth, K, Kopka, K, Choyke, PL, Holland-Letz, T, Haberkorn, U, Debus, J & Giesel, FL 2019, '68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients' Journal of Nuclear Medicine, vol. 60, no. 2, pp. 234-240. https://doi.org/10.2967/jnumed.118.211086
Koerber, Stefan A. ; Will, Leon ; Kratochwil, Clemens ; Haefner, Matthias F. ; Rathke, Hendrik ; Kremer, Christophe ; Merkle, Jonas ; Herfarth, Klaus ; Kopka, Klaus ; Choyke, Peter L. ; Holland-Letz, Tim ; Haberkorn, Uwe ; Debus, Juergen ; Giesel, Frederik L. / 68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma : Implications for radiotherapeutic management in 121 patients. In: Journal of Nuclear Medicine. 2019 ; Vol. 60, No. 2. pp. 234-240.
@article{2f0907671a0b40e28e4cce1079f338c5,
title = "68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients",
abstract = "The present study analyzed the impact of 68 Ga-labeled prostate-specific membrane antigen-HBED-CC ( 68 Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68 Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5{\%}) and 62 patients (51.2{\%}), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0{\%} and 44.0{\%} of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7{\%} and 56.3{\%}, respectively. Conclusion: 68 Ga-PSMA-11 PET/ CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.",
keywords = "PET/CT, PSMA, Prostate cancer, Radiotherapy, Staging",
author = "Koerber, {Stefan A.} and Leon Will and Clemens Kratochwil and Haefner, {Matthias F.} and Hendrik Rathke and Christophe Kremer and Jonas Merkle and Klaus Herfarth and Klaus Kopka and Choyke, {Peter L.} and Tim Holland-Letz and Uwe Haberkorn and Juergen Debus and Giesel, {Frederik L.}",
year = "2019",
month = "2",
day = "1",
doi = "10.2967/jnumed.118.211086",
language = "English (US)",
volume = "60",
pages = "234--240",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - 68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma

T2 - Implications for radiotherapeutic management in 121 patients

AU - Koerber, Stefan A.

AU - Will, Leon

AU - Kratochwil, Clemens

AU - Haefner, Matthias F.

AU - Rathke, Hendrik

AU - Kremer, Christophe

AU - Merkle, Jonas

AU - Herfarth, Klaus

AU - Kopka, Klaus

AU - Choyke, Peter L.

AU - Holland-Letz, Tim

AU - Haberkorn, Uwe

AU - Debus, Juergen

AU - Giesel, Frederik L.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The present study analyzed the impact of 68 Ga-labeled prostate-specific membrane antigen-HBED-CC ( 68 Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68 Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0% and 44.0% of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3%, respectively. Conclusion: 68 Ga-PSMA-11 PET/ CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.

AB - The present study analyzed the impact of 68 Ga-labeled prostate-specific membrane antigen-HBED-CC ( 68 Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68 Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0% and 44.0% of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3%, respectively. Conclusion: 68 Ga-PSMA-11 PET/ CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.

KW - PET/CT

KW - PSMA

KW - Prostate cancer

KW - Radiotherapy

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=85055597707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055597707&partnerID=8YFLogxK

U2 - 10.2967/jnumed.118.211086

DO - 10.2967/jnumed.118.211086

M3 - Article

VL - 60

SP - 234

EP - 240

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -